×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: covid | merck | molnupiravir | hospital | patients

UK Will Test Merck's COVID Pill With Hospitalized Patients

molnupiravir pills in bottle labeled Merck COVID-19 pills
(Dreamstime)

Monday, 24 January 2022 07:50 AM

British scientists will begin testing Merck and Ridgeback Biotherapeutics' antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19, amid the worldwide spread of the omicron variant.

The pill is approved in Britain for use in people with mild to moderate COVID-19, but it is not known whether it would work in patients hospitalized with severe illness, researchers of the RECOVERY trial said on Monday.

The study will compare 800 mg doses of molnupiravir, given twice daily for five days, with standard care for adult patients in hospitals because of COVID-19.

In 2020, the same scientists conducting the large trial showed that dexamethasone was able to save the lives of COVID patients in what was called a "major breakthrough" in the coronavirus pandemic.

"Adding molnupiravir (to the study) will allow us to study this drug on its own, but also in combination with other COVID-19 treatments," said Peter Horby, joint chief investigator of the trial and Oxford University professor.

Treatments that have been or being tested in the RECOVERY trial include arthritis drug tocilizumab, steroid dexamethasone, common antibiotic azithromycin, painkiller aspirin, and antibody treatments from Regeneron and GSK-Vir.

© 2022 Thomson/Reuters. All rights reserved.


Health-News
British scientists will begin testing Merck and Ridgeback Biotherapeutics' antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19, amid the worldwide spread of the omicron variant. The pill is approved in Britain for use in people with...
covid, merck, molnupiravir, hospital, patients
190
2022-50-24
Monday, 24 January 2022 07:50 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved